Biopharmaceutical company Trevena, Inc. is dedicated to developing and bringing to market innovative treatments for those living with central nervous system disorders. At the forefront of its product candidates are OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand engineered to manage moderate-to-severe acute pain, TRV250, a G protein biased delta-opioid receptor agonist designed to treat acute migraine, TRV734, a small molecule G protein biased ligand of the MOR targeting moderate-to-severe acute and chronic pain, and TRV045, a unique S1P modulator that takes on the challenge of chronic pain management. Founded in 2007 and headquartered in Chesterbrook, Pennsylvania, Trevena, Inc. stands poised to make a deep impact on the lives of those in need of advanced CNS treatments.
Trevena, Inc.'s ticker is TRVN
The company's shares trade on the NASDAQ stock exchange
They are based in Chesterbrook, Pennsylvania
There are 11-50 employees working at Trevena, Inc.
It is https://www.trevena.com/
Trevena, Inc. is in the Healthcare sector
Trevena, Inc. is in the Biotechnology industry
The following five companies are Trevena, Inc.'s industry peers: